JZL 184

Name: JZL 184
Brand: MedChemExpress
SKU: HY-15249
Rating: 5.0 (8 reviews)

Cat. No.: HY-15249 Purity: 99.46%: Data Sheet
COA

SDS
Handling Instructions
FAQs
Technical Support

JZL 184 is a potent, selective and irreversible MAGL inhibitor that blocks 2-Arachidonoylglycerol (2-AG) hydrolysis in brain membranes (IC₅₀ of 8 nM). JZL 184 displays >300-fold selectivity for MAGL over FAAH.

For research use only. We do not sell to patients.

CAS No. : 1101854-58-3

Size	Stock	Quantity

Free Sample (0.1 - 0.2 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 mg	In-stock	Estimated Time of Arrival: December 31
10 mg	In-stock	Estimated Time of Arrival: December 31
25 mg	In-stock	Estimated Time of Arrival: December 31
50 mg	In-stock	Estimated Time of Arrival: December 31
100 mg	In-stock	Estimated Time of Arrival: December 31
250 mg	In-stock	Estimated Time of Arrival: December 31
500 mg	In-stock	Estimated Time of Arrival: December 31
1 g	Get quote
5 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 8 publication(s) in Google Scholar

Other Forms of JZL 184:

JZL 184 (Standard) In-stock

8 Publications Citing Use of MCE JZL 184

In Vivo Efficacy Study

Cell Imaging/Staining

Flow Cytometry

: JZL 184 purchased from MedChemExpress. Usage Cited in: Research (Wash D C). 2025 Dec 9:8:1031. [Abstract]; JZL 184 (10 mg/kg; i.p.; 2 h) markedly improved both cephalic cutaneous allodynia and anxiety-like behaviors of ISDN-injected mice.

: JZL 184 purchased from MedChemExpress. Usage Cited in: Free Radic Biol Med. 2025 Nov 14:243:67-81. [Abstract]; JZL 184 (16 mg/kg; i.p.; once daily for 16 d) ameliorated GC-induced bone loss in C57BL/6J mice.

: JZL 184 purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2022 Oct 18;18(16):6114-6128.; JZL 184 (iMAGL) (20 nM; 12 h) significantly downregulated the number of LDs in fibroblasts (NIH 3T3 and MEF).

: JZL 184 purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2022 Oct 18;18(16):6114-6128.; The BODIPY staining (FITC) of fibroblasts (NIH 3T3 and MEF) that were treated with/without sodium oleate (50 µM) and JZL 184 (iMAGL) (20 nM; 12 h).

: JZL 184 purchased from MedChemExpress. Usage Cited in: Int J Biol Sci. 2022 Oct 18;18(16):6114-6128.; The protein expression of α-SMA and COL1A2 in fibroblasts (NIH 3T3 and MEF) that were treated with/without sodium oleate (50 µM) and JZL 184 (iMAGL) (20 nM; 24 h).

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target

IC50: 8 nM (2-Arachidonoylglycerol (2-AG) hydrolysis)^[1]

Cellular Effect

Cell Line	Type	Value	Description	References
COS-7	IC₅₀	0.002 μM Compound: 3, JZL184	Inhibition of human MAGL expressed in monkey COS7 cells Inhibition of human MAGL expressed in monkey COS7 cells	[PMID: 23455058]
COS-7	IC₅₀	0.008 μM Compound: 3, JZL184	Inhibition of recombinant MAGL (unknown origin) expressed in monkey COS7 cells Inhibition of recombinant MAGL (unknown origin) expressed in monkey COS7 cells	[PMID: 23455058]
COS-7	IC₅₀	0.025 μM Compound: 3, JZL184	Inhibition of rat MAGL expressed in monkey COS7 cells Inhibition of rat MAGL expressed in monkey COS7 cells	[PMID: 23455058]
COS-7	IC₅₀	2 nM Compound: JZL184	Inhibition of human MAGL expressed in COS7 cells using endogenous 2-AG substrate Inhibition of human MAGL expressed in COS7 cells using endogenous 2-AG substrate	[PMID: 22738638]
COS-7	IC₅₀	4 nM Compound: 6, JZL184	Inhibition of recombinant FAAH expressed in Cos7 cells after 30 mins by using anandamide as a substrate by LC-MS method Inhibition of recombinant FAAH expressed in Cos7 cells after 30 mins by using anandamide as a substrate by LC-MS method	[PMID: 19029917]
COS-7	IC₅₀	6 nM Compound: 6, JZL184	Inhibition of recombinant MAGL expressed in Cos7 cells after 30 mins by using 2-AG as a substrate by LC-MS method Inhibition of recombinant MAGL expressed in Cos7 cells after 30 mins by using 2-AG as a substrate by LC-MS method	[PMID: 19029917]
COS-7	IC₅₀	8 nM Compound: 3, JZL184	Inhibition of mouse recombinant MAGL expressed in african green monkey COS7 cells assessed as inhibition of 2-AG hydrolysis after 30 mins by LC-MS analysis Inhibition of mouse recombinant MAGL expressed in african green monkey COS7 cells assessed as inhibition of 2-AG hydrolysis after 30 mins by LC-MS analysis	[PMID: 21982493]

In Vitro

JZL 184 displays IC₅₀ values of 8 nM and 4 μM for blockade of 2-AG and oleamide (FAAH substrate) hydrolysis in brain membranes, respectively. Comparable inhibitory effects are observed with recombinant MAGL and FAAH when expressed in COS7 cells^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

JZL 184 (4-40 mg/kg; intraperitoneal injection; once; C57Bl/6 mice) treatment produces a rapid and sustained blockade of brain 2-AG hydrolase activity in mice, resulting in 8-fold elevations in endogenous 2-AG levels that are maintained for at least 8 h. JZL 184-treated mice shows a remarkable array of CB1-dependent behavioral effects, including analgesia, hypomotility, and hypothermia^[1].
JZL 184 prolongs depolarization-induced suppression of excitation (DSE) in Purkinje neurons in cerebellar slices and DSE inhibition (DSI) in CA1 pyramidal neurons in hippocampal slices. JZL 184 produces greater enhancement of DSE/DSI in mouse neurons than that in rat neurons^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male C57Bl/6 mice (6-8 weeks old, 20-26 g)^[1]
Dosage:	4 mg/kg, 8 mg/kg, 16 mg/kg, 40 mg/kg
Administration:	Intraperitoneal injection; once
Result:	Produced a rapid and sustained blockade of brain 2-AG hydrolase activity in mice, resulting in 8-fold elevations in endogenous 2-AG levels that were maintained for at least 8 h.

Molecular Weight

520.49

Formula

C₂₇H₂₄N₂O₉

CAS No.

1101854-58-3

Appearance

Solid

Color

White to off-white

SMILES

OC(C1=CC=C(OCO2)C2=C1)(C3CCN(C(OC4=CC=C([N+]([O-])=O)C=C4)=O)CC3)C5=CC(OCO6)=C6C=C5

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	1 year
	-20°C	6 months

Solvent & Solubility

In Vitro:

DMSO : ≥ 35 mg/mL (67.24 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	1.9213 mL	9.6063 mL	19.2127 mL
5 mM	0.3843 mL	1.9213 mL	3.8425 mL
10 mM	0.1921 mL	0.9606 mL	1.9213 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 1 year; -20°C, 6 months. When stored at -80°C, please use it within 1 year. When stored at -20°C, please use it within 6 months.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (4.80 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: 2.5 mg/mL (4.80 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (4.80 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.46%

Select Batch:

Data Sheet (283 KB) SDS (480 KB)

COA (259 KB) HNMR (140 KB) RP-HPLC (247 KB) LCMS (234 KB)

Handling Instructions (2659 KB)

References

[1]. Long JZ, et al. Selective blockade of 2-arachidonoylglycerol hydrolysis produces cannabinoid behavioral effects. Nat Chem Biol. 2009 Jan;5(1):37-44. [Content Brief]

[2]. Pan B, et al. Blockade of 2-arachidonoylglycerol hydrolysis by selective monoacylglycerol lipase inhibitor 4-nitrophenyl 4-(dibenzo[d][1,3]dioxol-5-yl(hydroxy)methyl)piperidine-1-carboxylate (JZL184) Enhances retrograde endocannabinoid signaling. J Pharmacol Exp Ther. 2009 Nov;331(2):591-7. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	1.9213 mL	9.6063 mL	19.2127 mL	48.0317 mL
	5 mM	0.3843 mL	1.9213 mL	3.8425 mL	9.6063 mL
	10 mM	0.1921 mL	0.9606 mL	1.9213 mL	4.8032 mL
	15 mM	0.1281 mL	0.6404 mL	1.2808 mL	3.2021 mL
	20 mM	0.0961 mL	0.4803 mL	0.9606 mL	2.4016 mL
	25 mM	0.0769 mL	0.3843 mL	0.7685 mL	1.9213 mL
	30 mM	0.0640 mL	0.3202 mL	0.6404 mL	1.6011 mL
	40 mM	0.0480 mL	0.2402 mL	0.4803 mL	1.2008 mL
	50 mM	0.0384 mL	0.1921 mL	0.3843 mL	0.9606 mL
	60 mM	0.0320 mL	0.1601 mL	0.3202 mL	0.8005 mL

JZL 184 Related Classifications

Neurological Disease

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

JZL 1841101854-58-3JZL184JZL-184MAGLMonoacylglycerol lipase2-ArachidonoylglycerolhydrolysisanalgesiaantinociceptiveneuronsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Requested Quantity *

Applicant Name *

Salutation

Email Address *

Phone Number *

Department

Organization Name *

City

State

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

JZL 184

Customer Review

Other Forms of JZL 184:

JZL 184 Related Antibodies

8 Publications Citing Use of MCE JZL 184

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

Biological Activity

Purity & Documentation

References

Customer Review

JZL 184 Related Antibodies

Molarity Calculator

Dilution Calculator

Complete Stock Solution Preparation Table

JZL 184 Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report